drugset / Trial / NCT05594342
Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support
RandomizedParallel-groupOpen-labelTreatment
Summary
Data regarding the safety and efficacy of ivabradine use in severely decompensated HFrEF requiring inotropic support is limited to case series.1 This study aimed to evaluate ivabradine safety and tolerability in admitted cardiogenic shock patients who started on dobutamine infusion for inotropic support.
Timeline
- Start
- 2022-07-01
- Primary completion
- 2023-01-01
- Completion
- 2023-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivabradine | Small molecule | 7.5 mg | Oral |
| Background | Dobutamine | Small molecule | — | — |